NASDAQ:DRTX - Durata Therapeutics Stock Price, Forecast & News

Durata Therapeutics trades on the NASDAQ under the ticker symbol "DRTX."

Media coverage about DRTX stock has trended extremely negative on Sunday, InfoTrie Sentiment reports. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Durata Therapeutics earned a coverage optimism score of -4.5 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Durata Therapeutics.

Some companies that are related to Durata Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Durata Therapeutics investors own include Allena Pharmaceuticals (ALNA), Arbutus Biopharma (ABUS), AcelRx Pharmaceuticals (ACRX), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Amicus Therapeutics (FOLD), Five Prime Therapeutics (FPRX), Glu Mobile (GLUU), Inovio Pharmaceuticals (INO) and Iovance Biotherapeutics (IOVA).

Durata Therapeutics' mailing address is 200 S Wacker Dr Ste 2550, CHICAGO, IL 60606-5811, United States. The biotechnology company can be reached via phone at +1-312-2197000.